Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Sara Lonardi et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Michael A. Morse et al.|Annals of Oncology|2022Cited by 253
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeUlrich Keilholz, Olivier Michielin, P.A. Ascierto et al.|Annals of Oncology|2020Cited by 232
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximabShasha Lv, Bart Neyns|International Journal of Oncology|2012Cited by 64
Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic MelanomaRenáta Váraljai, Alexander Roesch, Kilian Wistuba‐Hamprecht et al.|JCO Precision Oncology|2019Cited by 54